A	O
Multicenter	B:C1096776
Study	I:C1096776
of	O
Early	O
Anti-inflammatory	O
Treatment	O
in	O
Patients	O
With	O
Acute	O
Anterior	I:C2584975
Cruciate	I:C2584975
Ligament	I:C2584975
Tear	I:C2584975
.	O

A	O
Multicenter	O
Study	I:C1096776
of	O
Early	O
Anti-inflammatory	B:C0003209
Treatment	O
in	O
Patients	O
With	O
Acute	O
Anterior	I:C2584975
Cruciate	I:C2584975
Ligament	I:C2584975
Tear	I:C2584975
.	O

A	O
Multicenter	O
Study	I:C1096776
of	O
Early	O
Anti-inflammatory	O
Treatment	O
in	O
Patients	O
With	O
Acute	B:C2584975
Anterior	I:C2584975
Cruciate	I:C2584975
Ligament	I:C2584975
Tear	I:C2584975
.	O

It	O
is	O
increasingly	O
recognized	O
that	O
biochemical	O
abnormalities	B:C0221430
of	O
the	O
joint	O
precede	O
radiographic	O
abnormalities	I:C1704258
of	O
posttraumatic	O
osteoarthritis	I:C2894027
(	O
posttraumatic	O
osteoarthritis	I:C2894027
)	O
by	O
as	O
much	O
as	O
decades	O
.	O

It	O
is	O
increasingly	O
recognized	O
that	O
biochemical	O
abnormalities	O
of	O
the	O
joint	B:C0022417
precede	O
radiographic	O
abnormalities	I:C1704258
of	O
posttraumatic	O
osteoarthritis	I:C2894027
(	O
posttraumatic	O
osteoarthritis	I:C2894027
)	O
by	O
as	O
much	O
as	O
decades	O
.	O

It	O
is	O
increasingly	O
recognized	O
that	O
biochemical	O
abnormalities	O
of	O
the	O
joint	O
precede	O
radiographic	B:C1704258
abnormalities	I:C1704258
of	O
posttraumatic	O
osteoarthritis	I:C2894027
(	O
posttraumatic	O
osteoarthritis	I:C2894027
)	O
by	O
as	O
much	O
as	O
decades	O
.	O

It	O
is	O
increasingly	O
recognized	O
that	O
biochemical	O
abnormalities	O
of	O
the	O
joint	O
precede	O
radiographic	O
abnormalities	I:C1704258
of	O
posttraumatic	B:C2894027
osteoarthritis	I:C2894027
(	O
posttraumatic	O
osteoarthritis	I:C2894027
)	O
by	O
as	O
much	O
as	O
decades	O
.	O

It	O
is	O
increasingly	O
recognized	O
that	O
biochemical	O
abnormalities	O
of	O
the	O
joint	O
precede	O
radiographic	O
abnormalities	I:C1704258
of	O
posttraumatic	O
osteoarthritis	I:C2894027
(	O
posttraumatic	B:C2894027
osteoarthritis	I:C2894027
)	O
by	O
as	O
much	O
as	O
decades	O
.	O

A	O
growing	O
body	O
of	O
evidence	O
strongly	O
suggests	O
that	O
the	O
progression	B:C0242656
from	O
anterior	O
cruciate	I:C2584975
ligament	I:C2584975
(	I:C2584975
ACL	I:C2584975
)	I:C2584975
injury	I:C2584975
to	O
posttraumatic	O
osteoarthritis	I:C2894027
is	O
multifactorial	O
,	O
involving	O
the	O
interplay	O
between	O
biomechanical	O
disturbances	O
and	O
biochemical	O
homeostasis	O
of	O
articular	O
cartilage	I:C0007303
.	O

A	O
growing	O
body	O
of	O
evidence	O
strongly	O
suggests	O
that	O
the	O
progression	O
from	O
anterior	B:C2584975
cruciate	I:C2584975
ligament	I:C2584975
(	I:C2584975
ACL	I:C2584975
)	I:C2584975
injury	I:C2584975
to	O
posttraumatic	O
osteoarthritis	I:C2894027
is	O
multifactorial	O
,	O
involving	O
the	O
interplay	O
between	O
biomechanical	O
disturbances	O
and	O
biochemical	O
homeostasis	O
of	O
articular	O
cartilage	I:C0007303
.	O

A	O
growing	O
body	O
of	O
evidence	O
strongly	O
suggests	O
that	O
the	O
progression	O
from	O
anterior	O
cruciate	I:C2584975
ligament	I:C2584975
(	I:C2584975
ACL	I:C2584975
)	I:C2584975
injury	I:C2584975
to	O
posttraumatic	B:C2894027
osteoarthritis	I:C2894027
is	O
multifactorial	O
,	O
involving	O
the	O
interplay	O
between	O
biomechanical	O
disturbances	O
and	O
biochemical	O
homeostasis	O
of	O
articular	O
cartilage	I:C0007303
.	O

A	O
growing	O
body	O
of	O
evidence	O
strongly	O
suggests	O
that	O
the	O
progression	O
from	O
anterior	O
cruciate	I:C2584975
ligament	I:C2584975
(	I:C2584975
ACL	I:C2584975
)	I:C2584975
injury	I:C2584975
to	O
posttraumatic	O
osteoarthritis	I:C2894027
is	O
multifactorial	B:C1837655
,	O
involving	O
the	O
interplay	O
between	O
biomechanical	O
disturbances	O
and	O
biochemical	O
homeostasis	O
of	O
articular	O
cartilage	I:C0007303
.	O

A	O
growing	O
body	O
of	O
evidence	O
strongly	O
suggests	O
that	O
the	O
progression	O
from	O
anterior	O
cruciate	I:C2584975
ligament	I:C2584975
(	I:C2584975
ACL	I:C2584975
)	I:C2584975
injury	I:C2584975
to	O
posttraumatic	O
osteoarthritis	I:C2894027
is	O
multifactorial	O
,	O
involving	O
the	O
interplay	O
between	O
biomechanical	O
disturbances	O
and	O
biochemical	O
homeostasis	B:C0019868
of	O
articular	O
cartilage	I:C0007303
.	O

A	O
growing	O
body	O
of	O
evidence	O
strongly	O
suggests	O
that	O
the	O
progression	O
from	O
anterior	O
cruciate	I:C2584975
ligament	I:C2584975
(	I:C2584975
ACL	I:C2584975
)	I:C2584975
injury	I:C2584975
to	O
posttraumatic	O
osteoarthritis	I:C2894027
is	O
multifactorial	O
,	O
involving	O
the	O
interplay	O
between	O
biomechanical	O
disturbances	O
and	O
biochemical	O
homeostasis	O
of	O
articular	B:C0007303
cartilage	I:C0007303
.	O

The	O
purposes	O
of	O
this	O
randomized	B:C0242481
study	I:C0242481
using	O
an	O
acute	O
ACL	I:C2584975
injury	I:C2584975
model	O
were	O
to	O
(	O
1	O
)	O
evaluate	O
the	O
natural	O
progression	O
of	O
inflammatory	O
and	O
chondrodegenerative	O
biomarkers	I:C0005516
,	O
(	O
2	O
)	O
evaluate	O
the	O
relationship	O
between	O
subjective	O
reports	I:C0684224
of	O
pain	O
and	O
inflammatory	O
and	O
chondrodegenerative	O
biomarkers	I:C0005516
,	O
and	O
(	O
3	O
)	O
determine	O
if	O
postinjury	O
arthrocentesis	I:C0204854
and	O
corticosteroid	O
injection	O
offer	O
the	O
ability	O
to	O
alter	O
this	O
biochemical	O
cascade	I:C1704259
.	O

The	O
purposes	O
of	O
this	O
randomized	O
study	I:C0242481
using	O
an	O
acute	B:C2584975
ACL	I:C2584975
injury	I:C2584975
model	O
were	O
to	O
(	O
1	O
)	O
evaluate	O
the	O
natural	O
progression	O
of	O
inflammatory	O
and	O
chondrodegenerative	O
biomarkers	I:C0005516
,	O
(	O
2	O
)	O
evaluate	O
the	O
relationship	O
between	O
subjective	O
reports	I:C0684224
of	O
pain	O
and	O
inflammatory	O
and	O
chondrodegenerative	O
biomarkers	I:C0005516
,	O
and	O
(	O
3	O
)	O
determine	O
if	O
postinjury	O
arthrocentesis	I:C0204854
and	O
corticosteroid	O
injection	O
offer	O
the	O
ability	O
to	O
alter	O
this	O
biochemical	O
cascade	I:C1704259
.	O

The	O
purposes	O
of	O
this	O
randomized	O
study	I:C0242481
using	O
an	O
acute	O
ACL	I:C2584975
injury	I:C2584975
model	O
were	O
to	O
(	O
1	O
)	O
evaluate	O
the	O
natural	O
progression	O
of	O
inflammatory	B:C0005516
and	O
chondrodegenerative	O
biomarkers	I:C0005516
,	O
(	O
2	O
)	O
evaluate	O
the	O
relationship	O
between	O
subjective	O
reports	I:C0684224
of	O
pain	O
and	O
inflammatory	O
and	O
chondrodegenerative	O
biomarkers	I:C0005516
,	O
and	O
(	O
3	O
)	O
determine	O
if	O
postinjury	O
arthrocentesis	I:C0204854
and	O
corticosteroid	O
injection	O
offer	O
the	O
ability	O
to	O
alter	O
this	O
biochemical	O
cascade	I:C1704259
.	O

The	O
purposes	O
of	O
this	O
randomized	O
study	I:C0242481
using	O
an	O
acute	O
ACL	I:C2584975
injury	I:C2584975
model	O
were	O
to	O
(	O
1	O
)	O
evaluate	O
the	O
natural	O
progression	O
of	O
inflammatory	O
and	O
chondrodegenerative	B:C0005516
biomarkers	I:C0005516
,	O
(	O
2	O
)	O
evaluate	O
the	O
relationship	O
between	O
subjective	O
reports	I:C0684224
of	O
pain	O
and	O
inflammatory	O
and	O
chondrodegenerative	O
biomarkers	I:C0005516
,	O
and	O
(	O
3	O
)	O
determine	O
if	O
postinjury	O
arthrocentesis	I:C0204854
and	O
corticosteroid	O
injection	O
offer	O
the	O
ability	O
to	O
alter	O
this	O
biochemical	O
cascade	I:C1704259
.	O

The	O
purposes	O
of	O
this	O
randomized	O
study	I:C0242481
using	O
an	O
acute	O
ACL	I:C2584975
injury	I:C2584975
model	O
were	O
to	O
(	O
1	O
)	O
evaluate	O
the	O
natural	O
progression	O
of	O
inflammatory	O
and	O
chondrodegenerative	O
biomarkers	I:C0005516
,	O
(	O
2	O
)	O
evaluate	O
the	O
relationship	O
between	O
subjective	B:C0684224
reports	I:C0684224
of	O
pain	O
and	O
inflammatory	O
and	O
chondrodegenerative	O
biomarkers	I:C0005516
,	O
and	O
(	O
3	O
)	O
determine	O
if	O
postinjury	O
arthrocentesis	I:C0204854
and	O
corticosteroid	O
injection	O
offer	O
the	O
ability	O
to	O
alter	O
this	O
biochemical	O
cascade	I:C1704259
.	O

The	O
purposes	O
of	O
this	O
randomized	O
study	I:C0242481
using	O
an	O
acute	O
ACL	I:C2584975
injury	I:C2584975
model	O
were	O
to	O
(	O
1	O
)	O
evaluate	O
the	O
natural	O
progression	O
of	O
inflammatory	O
and	O
chondrodegenerative	O
biomarkers	I:C0005516
,	O
(	O
2	O
)	O
evaluate	O
the	O
relationship	O
between	O
subjective	O
reports	I:C0684224
of	O
pain	B:C0030193
and	O
inflammatory	O
and	O
chondrodegenerative	O
biomarkers	I:C0005516
,	O
and	O
(	O
3	O
)	O
determine	O
if	O
postinjury	O
arthrocentesis	I:C0204854
and	O
corticosteroid	O
injection	O
offer	O
the	O
ability	O
to	O
alter	O
this	O
biochemical	O
cascade	I:C1704259
.	O

The	O
purposes	O
of	O
this	O
randomized	O
study	I:C0242481
using	O
an	O
acute	O
ACL	I:C2584975
injury	I:C2584975
model	O
were	O
to	O
(	O
1	O
)	O
evaluate	O
the	O
natural	O
progression	O
of	O
inflammatory	O
and	O
chondrodegenerative	O
biomarkers	I:C0005516
,	O
(	O
2	O
)	O
evaluate	O
the	O
relationship	O
between	O
subjective	O
reports	I:C0684224
of	O
pain	O
and	O
inflammatory	B:C0005516
and	O
chondrodegenerative	O
biomarkers	I:C0005516
,	O
and	O
(	O
3	O
)	O
determine	O
if	O
postinjury	O
arthrocentesis	I:C0204854
and	O
corticosteroid	O
injection	O
offer	O
the	O
ability	O
to	O
alter	O
this	O
biochemical	O
cascade	I:C1704259
.	O

The	O
purposes	O
of	O
this	O
randomized	O
study	I:C0242481
using	O
an	O
acute	O
ACL	I:C2584975
injury	I:C2584975
model	O
were	O
to	O
(	O
1	O
)	O
evaluate	O
the	O
natural	O
progression	O
of	O
inflammatory	O
and	O
chondrodegenerative	O
biomarkers	I:C0005516
,	O
(	O
2	O
)	O
evaluate	O
the	O
relationship	O
between	O
subjective	O
reports	I:C0684224
of	O
pain	O
and	O
inflammatory	O
and	O
chondrodegenerative	B:C0005516
biomarkers	I:C0005516
,	O
and	O
(	O
3	O
)	O
determine	O
if	O
postinjury	O
arthrocentesis	I:C0204854
and	O
corticosteroid	O
injection	O
offer	O
the	O
ability	O
to	O
alter	O
this	O
biochemical	O
cascade	I:C1704259
.	O

The	O
purposes	O
of	O
this	O
randomized	O
study	I:C0242481
using	O
an	O
acute	O
ACL	I:C2584975
injury	I:C2584975
model	O
were	O
to	O
(	O
1	O
)	O
evaluate	O
the	O
natural	O
progression	O
of	O
inflammatory	O
and	O
chondrodegenerative	O
biomarkers	I:C0005516
,	O
(	O
2	O
)	O
evaluate	O
the	O
relationship	O
between	O
subjective	O
reports	I:C0684224
of	O
pain	O
and	O
inflammatory	O
and	O
chondrodegenerative	O
biomarkers	I:C0005516
,	O
and	O
(	O
3	O
)	O
determine	O
if	O
postinjury	B:C0204854
arthrocentesis	I:C0204854
and	O
corticosteroid	O
injection	O
offer	O
the	O
ability	O
to	O
alter	O
this	O
biochemical	O
cascade	I:C1704259
.	O

The	O
purposes	O
of	O
this	O
randomized	O
study	I:C0242481
using	O
an	O
acute	O
ACL	I:C2584975
injury	I:C2584975
model	O
were	O
to	O
(	O
1	O
)	O
evaluate	O
the	O
natural	O
progression	O
of	O
inflammatory	O
and	O
chondrodegenerative	O
biomarkers	I:C0005516
,	O
(	O
2	O
)	O
evaluate	O
the	O
relationship	O
between	O
subjective	O
reports	I:C0684224
of	O
pain	O
and	O
inflammatory	O
and	O
chondrodegenerative	O
biomarkers	I:C0005516
,	O
and	O
(	O
3	O
)	O
determine	O
if	O
postinjury	O
arthrocentesis	I:C0204854
and	O
corticosteroid	B:C3536709
injection	O
offer	O
the	O
ability	O
to	O
alter	O
this	O
biochemical	O
cascade	I:C1704259
.	O

The	O
purposes	O
of	O
this	O
randomized	O
study	I:C0242481
using	O
an	O
acute	O
ACL	I:C2584975
injury	I:C2584975
model	O
were	O
to	O
(	O
1	O
)	O
evaluate	O
the	O
natural	O
progression	O
of	O
inflammatory	O
and	O
chondrodegenerative	O
biomarkers	I:C0005516
,	O
(	O
2	O
)	O
evaluate	O
the	O
relationship	O
between	O
subjective	O
reports	I:C0684224
of	O
pain	O
and	O
inflammatory	O
and	O
chondrodegenerative	O
biomarkers	I:C0005516
,	O
and	O
(	O
3	O
)	O
determine	O
if	O
postinjury	O
arthrocentesis	I:C0204854
and	O
corticosteroid	O
injection	B:C0021485
offer	O
the	O
ability	O
to	O
alter	O
this	O
biochemical	O
cascade	I:C1704259
.	O

The	O
purposes	O
of	O
this	O
randomized	O
study	I:C0242481
using	O
an	O
acute	O
ACL	I:C2584975
injury	I:C2584975
model	O
were	O
to	O
(	O
1	O
)	O
evaluate	O
the	O
natural	O
progression	O
of	O
inflammatory	O
and	O
chondrodegenerative	O
biomarkers	I:C0005516
,	O
(	O
2	O
)	O
evaluate	O
the	O
relationship	O
between	O
subjective	O
reports	I:C0684224
of	O
pain	O
and	O
inflammatory	O
and	O
chondrodegenerative	O
biomarkers	I:C0005516
,	O
and	O
(	O
3	O
)	O
determine	O
if	O
postinjury	O
arthrocentesis	I:C0204854
and	O
corticosteroid	O
injection	O
offer	O
the	O
ability	O
to	O
alter	O
this	O
biochemical	B:C1704259
cascade	I:C1704259
.	O

Randomized	B:C0206035
controlled	I:C0206035
trial	I:C0206035
;	O
Level	O
of	O
evidence	O
,	O
2	O
.	O
A	O
total	O
of	O
49	O
patients	O
were	O
randomized	O
to	O
4	O
groups	O
:	O
group	O
1	I:C0441861
(	O
corticosteroid	O
at	O
4	O
days	O
after	O
ACL	O
injury	I:C2584975
,	O
placebo	O
injection	O
of	O
saline	O
at	O
2	O
weeks	O
)	O
,	O
group	O
2	I:C0441865
(	O
placebo	O
at	O
4	O
days	O
after	O
ACL	O
injury	I:C2584975
,	O
corticosteroid	O
at	O
2	O
weeks	O
)	O
,	O
group	O
3	I:C0441869
(	O
corticosteroid	O
at	O
both	O
time	O
intervals	O
)	O
,	O
or	O
a	O
placebo	O
group	O
(	O
saline	O
injections	O
at	O
both	O
time	O
intervals	O
)	O
.	O

Randomized	O
controlled	I:C0206035
trial	I:C0206035
;	O
Level	O
of	O
evidence	O
,	O
2	O
.	O
A	O
total	O
of	O
49	O
patients	O
were	O
randomized	B:C0034656
to	O
4	O
groups	O
:	O
group	O
1	I:C0441861
(	O
corticosteroid	O
at	O
4	O
days	O
after	O
ACL	O
injury	I:C2584975
,	O
placebo	O
injection	O
of	O
saline	O
at	O
2	O
weeks	O
)	O
,	O
group	O
2	I:C0441865
(	O
placebo	O
at	O
4	O
days	O
after	O
ACL	O
injury	I:C2584975
,	O
corticosteroid	O
at	O
2	O
weeks	O
)	O
,	O
group	O
3	I:C0441869
(	O
corticosteroid	O
at	O
both	O
time	O
intervals	O
)	O
,	O
or	O
a	O
placebo	O
group	O
(	O
saline	O
injections	O
at	O
both	O
time	O
intervals	O
)	O
.	O

Randomized	O
controlled	I:C0206035
trial	I:C0206035
;	O
Level	O
of	O
evidence	O
,	O
2	O
.	O
A	O
total	O
of	O
49	O
patients	O
were	O
randomized	O
to	O
4	O
groups	O
:	O
group	B:C0441861
1	I:C0441861
(	O
corticosteroid	O
at	O
4	O
days	O
after	O
ACL	O
injury	I:C2584975
,	O
placebo	O
injection	O
of	O
saline	O
at	O
2	O
weeks	O
)	O
,	O
group	O
2	I:C0441865
(	O
placebo	O
at	O
4	O
days	O
after	O
ACL	O
injury	I:C2584975
,	O
corticosteroid	O
at	O
2	O
weeks	O
)	O
,	O
group	O
3	I:C0441869
(	O
corticosteroid	O
at	O
both	O
time	O
intervals	O
)	O
,	O
or	O
a	O
placebo	O
group	O
(	O
saline	O
injections	O
at	O
both	O
time	O
intervals	O
)	O
.	O

Randomized	O
controlled	I:C0206035
trial	I:C0206035
;	O
Level	O
of	O
evidence	O
,	O
2	O
.	O
A	O
total	O
of	O
49	O
patients	O
were	O
randomized	O
to	O
4	O
groups	O
:	O
group	O
1	I:C0441861
(	O
corticosteroid	B:C3536709
at	O
4	O
days	O
after	O
ACL	O
injury	I:C2584975
,	O
placebo	O
injection	O
of	O
saline	O
at	O
2	O
weeks	O
)	O
,	O
group	O
2	I:C0441865
(	O
placebo	O
at	O
4	O
days	O
after	O
ACL	O
injury	I:C2584975
,	O
corticosteroid	O
at	O
2	O
weeks	O
)	O
,	O
group	O
3	I:C0441869
(	O
corticosteroid	O
at	O
both	O
time	O
intervals	O
)	O
,	O
or	O
a	O
placebo	O
group	O
(	O
saline	O
injections	O
at	O
both	O
time	O
intervals	O
)	O
.	O

Randomized	O
controlled	I:C0206035
trial	I:C0206035
;	O
Level	O
of	O
evidence	O
,	O
2	O
.	O
A	O
total	O
of	O
49	O
patients	O
were	O
randomized	O
to	O
4	O
groups	O
:	O
group	O
1	I:C0441861
(	O
corticosteroid	O
at	O
4	O
days	O
after	O
ACL	B:C2584975
injury	I:C2584975
,	O
placebo	O
injection	O
of	O
saline	O
at	O
2	O
weeks	O
)	O
,	O
group	O
2	I:C0441865
(	O
placebo	O
at	O
4	O
days	O
after	O
ACL	O
injury	I:C2584975
,	O
corticosteroid	O
at	O
2	O
weeks	O
)	O
,	O
group	O
3	I:C0441869
(	O
corticosteroid	O
at	O
both	O
time	O
intervals	O
)	O
,	O
or	O
a	O
placebo	O
group	O
(	O
saline	O
injections	O
at	O
both	O
time	O
intervals	O
)	O
.	O

Randomized	O
controlled	I:C0206035
trial	I:C0206035
;	O
Level	O
of	O
evidence	O
,	O
2	O
.	O
A	O
total	O
of	O
49	O
patients	O
were	O
randomized	O
to	O
4	O
groups	O
:	O
group	O
1	I:C0441861
(	O
corticosteroid	O
at	O
4	O
days	O
after	O
ACL	O
injury	I:C2584975
,	O
placebo	B:C1696465
injection	O
of	O
saline	O
at	O
2	O
weeks	O
)	O
,	O
group	O
2	I:C0441865
(	O
placebo	O
at	O
4	O
days	O
after	O
ACL	O
injury	I:C2584975
,	O
corticosteroid	O
at	O
2	O
weeks	O
)	O
,	O
group	O
3	I:C0441869
(	O
corticosteroid	O
at	O
both	O
time	O
intervals	O
)	O
,	O
or	O
a	O
placebo	O
group	O
(	O
saline	O
injections	O
at	O
both	O
time	O
intervals	O
)	O
.	O

Randomized	O
controlled	I:C0206035
trial	I:C0206035
;	O
Level	O
of	O
evidence	O
,	O
2	O
.	O
A	O
total	O
of	O
49	O
patients	O
were	O
randomized	O
to	O
4	O
groups	O
:	O
group	O
1	I:C0441861
(	O
corticosteroid	O
at	O
4	O
days	O
after	O
ACL	O
injury	I:C2584975
,	O
placebo	O
injection	B:C1533685
of	O
saline	O
at	O
2	O
weeks	O
)	O
,	O
group	O
2	I:C0441865
(	O
placebo	O
at	O
4	O
days	O
after	O
ACL	O
injury	I:C2584975
,	O
corticosteroid	O
at	O
2	O
weeks	O
)	O
,	O
group	O
3	I:C0441869
(	O
corticosteroid	O
at	O
both	O
time	O
intervals	O
)	O
,	O
or	O
a	O
placebo	O
group	O
(	O
saline	O
injections	O
at	O
both	O
time	O
intervals	O
)	O
.	O

Randomized	O
controlled	I:C0206035
trial	I:C0206035
;	O
Level	O
of	O
evidence	O
,	O
2	O
.	O
A	O
total	O
of	O
49	O
patients	O
were	O
randomized	O
to	O
4	O
groups	O
:	O
group	O
1	I:C0441861
(	O
corticosteroid	O
at	O
4	O
days	O
after	O
ACL	O
injury	I:C2584975
,	O
placebo	O
injection	O
of	O
saline	O
at	O
2	O
weeks	O
)	O
,	O
group	B:C0441865
2	I:C0441865
(	O
placebo	O
at	O
4	O
days	O
after	O
ACL	O
injury	I:C2584975
,	O
corticosteroid	O
at	O
2	O
weeks	O
)	O
,	O
group	O
3	I:C0441869
(	O
corticosteroid	O
at	O
both	O
time	O
intervals	O
)	O
,	O
or	O
a	O
placebo	O
group	O
(	O
saline	O
injections	O
at	O
both	O
time	O
intervals	O
)	O
.	O

Randomized	O
controlled	I:C0206035
trial	I:C0206035
;	O
Level	O
of	O
evidence	O
,	O
2	O
.	O
A	O
total	O
of	O
49	O
patients	O
were	O
randomized	O
to	O
4	O
groups	O
:	O
group	O
1	I:C0441861
(	O
corticosteroid	O
at	O
4	O
days	O
after	O
ACL	O
injury	I:C2584975
,	O
placebo	O
injection	O
of	O
saline	O
at	O
2	O
weeks	O
)	O
,	O
group	O
2	I:C0441865
(	O
placebo	B:C1696465
at	O
4	O
days	O
after	O
ACL	O
injury	I:C2584975
,	O
corticosteroid	O
at	O
2	O
weeks	O
)	O
,	O
group	O
3	I:C0441869
(	O
corticosteroid	O
at	O
both	O
time	O
intervals	O
)	O
,	O
or	O
a	O
placebo	O
group	O
(	O
saline	O
injections	O
at	O
both	O
time	O
intervals	O
)	O
.	O

Randomized	O
controlled	I:C0206035
trial	I:C0206035
;	O
Level	O
of	O
evidence	O
,	O
2	O
.	O
A	O
total	O
of	O
49	O
patients	O
were	O
randomized	O
to	O
4	O
groups	O
:	O
group	O
1	I:C0441861
(	O
corticosteroid	O
at	O
4	O
days	O
after	O
ACL	O
injury	I:C2584975
,	O
placebo	O
injection	O
of	O
saline	O
at	O
2	O
weeks	O
)	O
,	O
group	O
2	I:C0441865
(	O
placebo	O
at	O
4	O
days	O
after	O
ACL	B:C2584975
injury	I:C2584975
,	O
corticosteroid	O
at	O
2	O
weeks	O
)	O
,	O
group	O
3	I:C0441869
(	O
corticosteroid	O
at	O
both	O
time	O
intervals	O
)	O
,	O
or	O
a	O
placebo	O
group	O
(	O
saline	O
injections	O
at	O
both	O
time	O
intervals	O
)	O
.	O

Randomized	O
controlled	I:C0206035
trial	I:C0206035
;	O
Level	O
of	O
evidence	O
,	O
2	O
.	O
A	O
total	O
of	O
49	O
patients	O
were	O
randomized	O
to	O
4	O
groups	O
:	O
group	O
1	I:C0441861
(	O
corticosteroid	O
at	O
4	O
days	O
after	O
ACL	O
injury	I:C2584975
,	O
placebo	O
injection	O
of	O
saline	O
at	O
2	O
weeks	O
)	O
,	O
group	O
2	I:C0441865
(	O
placebo	O
at	O
4	O
days	O
after	O
ACL	O
injury	I:C2584975
,	O
corticosteroid	B:C3536709
at	O
2	O
weeks	O
)	O
,	O
group	O
3	I:C0441869
(	O
corticosteroid	O
at	O
both	O
time	O
intervals	O
)	O
,	O
or	O
a	O
placebo	O
group	O
(	O
saline	O
injections	O
at	O
both	O
time	O
intervals	O
)	O
.	O

Randomized	O
controlled	I:C0206035
trial	I:C0206035
;	O
Level	O
of	O
evidence	O
,	O
2	O
.	O
A	O
total	O
of	O
49	O
patients	O
were	O
randomized	O
to	O
4	O
groups	O
:	O
group	O
1	I:C0441861
(	O
corticosteroid	O
at	O
4	O
days	O
after	O
ACL	O
injury	I:C2584975
,	O
placebo	O
injection	O
of	O
saline	O
at	O
2	O
weeks	O
)	O
,	O
group	O
2	I:C0441865
(	O
placebo	O
at	O
4	O
days	O
after	O
ACL	O
injury	I:C2584975
,	O
corticosteroid	O
at	O
2	O
weeks	O
)	O
,	O
group	B:C0441869
3	I:C0441869
(	O
corticosteroid	O
at	O
both	O
time	O
intervals	O
)	O
,	O
or	O
a	O
placebo	O
group	O
(	O
saline	O
injections	O
at	O
both	O
time	O
intervals	O
)	O
.	O

Randomized	O
controlled	I:C0206035
trial	I:C0206035
;	O
Level	O
of	O
evidence	O
,	O
2	O
.	O
A	O
total	O
of	O
49	O
patients	O
were	O
randomized	O
to	O
4	O
groups	O
:	O
group	O
1	I:C0441861
(	O
corticosteroid	O
at	O
4	O
days	O
after	O
ACL	O
injury	I:C2584975
,	O
placebo	O
injection	O
of	O
saline	O
at	O
2	O
weeks	O
)	O
,	O
group	O
2	I:C0441865
(	O
placebo	O
at	O
4	O
days	O
after	O
ACL	O
injury	I:C2584975
,	O
corticosteroid	O
at	O
2	O
weeks	O
)	O
,	O
group	O
3	I:C0441869
(	O
corticosteroid	B:C3536709
at	O
both	O
time	O
intervals	O
)	O
,	O
or	O
a	O
placebo	O
group	O
(	O
saline	O
injections	O
at	O
both	O
time	O
intervals	O
)	O
.	O

Randomized	O
controlled	I:C0206035
trial	I:C0206035
;	O
Level	O
of	O
evidence	O
,	O
2	O
.	O
A	O
total	O
of	O
49	O
patients	O
were	O
randomized	O
to	O
4	O
groups	O
:	O
group	O
1	I:C0441861
(	O
corticosteroid	O
at	O
4	O
days	O
after	O
ACL	O
injury	I:C2584975
,	O
placebo	O
injection	O
of	O
saline	O
at	O
2	O
weeks	O
)	O
,	O
group	O
2	I:C0441865
(	O
placebo	O
at	O
4	O
days	O
after	O
ACL	O
injury	I:C2584975
,	O
corticosteroid	O
at	O
2	O
weeks	O
)	O
,	O
group	O
3	I:C0441869
(	O
corticosteroid	O
at	O
both	O
time	O
intervals	O
)	O
,	O
or	O
a	O
placebo	B:C1696465
group	O
(	O
saline	O
injections	O
at	O
both	O
time	O
intervals	O
)	O
.	O

Randomized	O
controlled	I:C0206035
trial	I:C0206035
;	O
Level	O
of	O
evidence	O
,	O
2	O
.	O
A	O
total	O
of	O
49	O
patients	O
were	O
randomized	O
to	O
4	O
groups	O
:	O
group	O
1	I:C0441861
(	O
corticosteroid	O
at	O
4	O
days	O
after	O
ACL	O
injury	I:C2584975
,	O
placebo	O
injection	O
of	O
saline	O
at	O
2	O
weeks	O
)	O
,	O
group	O
2	I:C0441865
(	O
placebo	O
at	O
4	O
days	O
after	O
ACL	O
injury	I:C2584975
,	O
corticosteroid	O
at	O
2	O
weeks	O
)	O
,	O
group	O
3	I:C0441869
(	O
corticosteroid	O
at	O
both	O
time	O
intervals	O
)	O
,	O
or	O
a	O
placebo	O
group	O
(	O
saline	O
injections	B:C1533685
at	O
both	O
time	O
intervals	O
)	O
.	O

Patient	B:C4277735
-	I:C4277735
reported	I:C4277735
outcome	I:C4277735
measures	I:C4277735
and	O
synovial	O
biomarkers	O
were	O
collected	O
at	O
approximately	O
4	O
days	O
,	O
11	O
days	O
,	O
and	O
5	O
weeks	O
after	O
injury	O
.	O

Patient	O
-	I:C4277735
reported	I:C4277735
outcome	I:C4277735
measures	I:C4277735
and	O
synovial	O
biomarkers	B:C0005516
were	O
collected	O
at	O
approximately	O
4	O
days	O
,	O
11	O
days	O
,	O
and	O
5	O
weeks	O
after	O
injury	O
.	O

Patient	O
-	I:C4277735
reported	I:C4277735
outcome	I:C4277735
measures	I:C4277735
and	O
synovial	O
biomarkers	O
were	O
collected	O
at	O
approximately	O
4	O
days	O
,	O
11	O
days	O
,	O
and	O
5	O
weeks	O
after	O
injury	B:C3263723
.	O

The	O
change	O
between	O
the	O
time	O
points	O
was	O
assessed	O
for	O
all	O
variables	O
using	O
Wilcoxon	B:C0871608
tests	I:C0871608
,	O
and	O
the	O
relationship	O
between	O
changes	O
in	O
outcome	O
scores	I:C4274403
and	O
biomarkers	O
were	O
assessed	O
by	O
calculating	O
Spearman	O
ρ.	O
Outcomes	O
and	O
biomarkers	O
were	O
also	O
compared	O
between	O
the	O
4	O
groups	O
using	O
Kruskal	O
-	I:C1708614
Wallis	I:C1708614
tests	I:C1708614
.	O

The	O
change	O
between	O
the	O
time	O
points	O
was	O
assessed	O
for	O
all	O
variables	O
using	O
Wilcoxon	O
tests	I:C0871608
,	O
and	O
the	O
relationship	O
between	O
changes	O
in	O
outcome	B:C4274403
scores	I:C4274403
and	O
biomarkers	O
were	O
assessed	O
by	O
calculating	O
Spearman	O
ρ.	O
Outcomes	O
and	O
biomarkers	O
were	O
also	O
compared	O
between	O
the	O
4	O
groups	O
using	O
Kruskal	O
-	I:C1708614
Wallis	I:C1708614
tests	I:C1708614
.	O

The	O
change	O
between	O
the	O
time	O
points	O
was	O
assessed	O
for	O
all	O
variables	O
using	O
Wilcoxon	O
tests	I:C0871608
,	O
and	O
the	O
relationship	O
between	O
changes	O
in	O
outcome	O
scores	I:C4274403
and	O
biomarkers	B:C0005516
were	O
assessed	O
by	O
calculating	O
Spearman	O
ρ.	O
Outcomes	O
and	O
biomarkers	O
were	O
also	O
compared	O
between	O
the	O
4	O
groups	O
using	O
Kruskal	O
-	I:C1708614
Wallis	I:C1708614
tests	I:C1708614
.	O

The	O
change	O
between	O
the	O
time	O
points	O
was	O
assessed	O
for	O
all	O
variables	O
using	O
Wilcoxon	O
tests	I:C0871608
,	O
and	O
the	O
relationship	O
between	O
changes	O
in	O
outcome	O
scores	I:C4274403
and	O
biomarkers	O
were	O
assessed	O
by	O
calculating	O
Spearman	O
ρ.	O
Outcomes	O
and	O
biomarkers	B:C0005516
were	O
also	O
compared	O
between	O
the	O
4	O
groups	O
using	O
Kruskal	O
-	I:C1708614
Wallis	I:C1708614
tests	I:C1708614
.	O

The	O
change	O
between	O
the	O
time	O
points	O
was	O
assessed	O
for	O
all	O
variables	O
using	O
Wilcoxon	O
tests	I:C0871608
,	O
and	O
the	O
relationship	O
between	O
changes	O
in	O
outcome	O
scores	I:C4274403
and	O
biomarkers	O
were	O
assessed	O
by	O
calculating	O
Spearman	O
ρ.	O
Outcomes	O
and	O
biomarkers	O
were	O
also	O
compared	O
between	O
the	O
4	O
groups	O
using	O
Kruskal	B:C1708614
-	I:C1708614
Wallis	I:C1708614
tests	I:C1708614
.	O

No	B:C1963761
adverse	I:C1963761
events	I:C1963761
or	O
infections	O
were	O
observed	O
in	O
any	O
study	O
patients	O
.	O

No	O
adverse	I:C1963761
events	I:C1963761
or	O
infections	B:C3714514
were	O
observed	O
in	O
any	O
study	O
patients	O
.	O

No	O
adverse	I:C1963761
events	I:C1963761
or	O
infections	O
were	O
observed	O
in	O
any	O
study	B:C2603343
patients	O
.	O

With	O
the	O
exception	O
of	O
matrix	B:C0127082
metalloproteinase	I:C0127082
1	I:C0127082
(	O
matrix	O
metalloproteinase	I:C0127082
1	I:C0127082
)	O
and	O
tumor	O
necrosis	I:C0033684
factor	I:C0033684
-	I:C0033684
inducible	I:C0033684
gene	I:C0033684
6	I:C0033684
(	O
tumor	O
necrosis	I:C0033684
factor	I:C0033684
-	I:C0033684
inducible	I:C0033684
gene	I:C0033684
6	I:C0033684
)	O
,	O
chondrodegenerative	O
markers	I:C0005516
worsened	O
over	O
the	O
first	O
5	O
weeks	O
while	O
all	O
patient	O
-	I:C2987124
reported	I:C2987124
outcomes	I:C2987124
improved	O
during	O
this	O
time	O
,	O
regardless	O
of	O
treatment	O
group	O
.	O

With	O
the	O
exception	O
of	O
matrix	O
metalloproteinase	I:C0127082
1	I:C0127082
(	O
matrix	B:C0127082
metalloproteinase	I:C0127082
1	I:C0127082
)	O
and	O
tumor	O
necrosis	I:C0033684
factor	I:C0033684
-	I:C0033684
inducible	I:C0033684
gene	I:C0033684
6	I:C0033684
(	O
tumor	O
necrosis	I:C0033684
factor	I:C0033684
-	I:C0033684
inducible	I:C0033684
gene	I:C0033684
6	I:C0033684
)	O
,	O
chondrodegenerative	O
markers	I:C0005516
worsened	O
over	O
the	O
first	O
5	O
weeks	O
while	O
all	O
patient	O
-	I:C2987124
reported	I:C2987124
outcomes	I:C2987124
improved	O
during	O
this	O
time	O
,	O
regardless	O
of	O
treatment	O
group	O
.	O

With	O
the	O
exception	O
of	O
matrix	O
metalloproteinase	I:C0127082
1	I:C0127082
(	O
matrix	O
metalloproteinase	I:C0127082
1	I:C0127082
)	O
and	O
tumor	B:C0033684
necrosis	I:C0033684
factor	I:C0033684
-	I:C0033684
inducible	I:C0033684
gene	I:C0033684
6	I:C0033684
(	O
tumor	O
necrosis	I:C0033684
factor	I:C0033684
-	I:C0033684
inducible	I:C0033684
gene	I:C0033684
6	I:C0033684
)	O
,	O
chondrodegenerative	O
markers	I:C0005516
worsened	O
over	O
the	O
first	O
5	O
weeks	O
while	O
all	O
patient	O
-	I:C2987124
reported	I:C2987124
outcomes	I:C2987124
improved	O
during	O
this	O
time	O
,	O
regardless	O
of	O
treatment	O
group	O
.	O

With	O
the	O
exception	O
of	O
matrix	O
metalloproteinase	I:C0127082
1	I:C0127082
(	O
matrix	O
metalloproteinase	I:C0127082
1	I:C0127082
)	O
and	O
tumor	O
necrosis	I:C0033684
factor	I:C0033684
-	I:C0033684
inducible	I:C0033684
gene	I:C0033684
6	I:C0033684
(	O
tumor	B:C0033684
necrosis	I:C0033684
factor	I:C0033684
-	I:C0033684
inducible	I:C0033684
gene	I:C0033684
6	I:C0033684
)	O
,	O
chondrodegenerative	O
markers	I:C0005516
worsened	O
over	O
the	O
first	O
5	O
weeks	O
while	O
all	O
patient	O
-	I:C2987124
reported	I:C2987124
outcomes	I:C2987124
improved	O
during	O
this	O
time	O
,	O
regardless	O
of	O
treatment	O
group	O
.	O

With	O
the	O
exception	O
of	O
matrix	O
metalloproteinase	I:C0127082
1	I:C0127082
(	O
matrix	O
metalloproteinase	I:C0127082
1	I:C0127082
)	O
and	O
tumor	O
necrosis	I:C0033684
factor	I:C0033684
-	I:C0033684
inducible	I:C0033684
gene	I:C0033684
6	I:C0033684
(	O
tumor	O
necrosis	I:C0033684
factor	I:C0033684
-	I:C0033684
inducible	I:C0033684
gene	I:C0033684
6	I:C0033684
)	O
,	O
chondrodegenerative	B:C0005516
markers	I:C0005516
worsened	O
over	O
the	O
first	O
5	O
weeks	O
while	O
all	O
patient	O
-	I:C2987124
reported	I:C2987124
outcomes	I:C2987124
improved	O
during	O
this	O
time	O
,	O
regardless	O
of	O
treatment	O
group	O
.	O

With	O
the	O
exception	O
of	O
matrix	O
metalloproteinase	I:C0127082
1	I:C0127082
(	O
matrix	O
metalloproteinase	I:C0127082
1	I:C0127082
)	O
and	O
tumor	O
necrosis	I:C0033684
factor	I:C0033684
-	I:C0033684
inducible	I:C0033684
gene	I:C0033684
6	I:C0033684
(	O
tumor	O
necrosis	I:C0033684
factor	I:C0033684
-	I:C0033684
inducible	I:C0033684
gene	I:C0033684
6	I:C0033684
)	O
,	O
chondrodegenerative	O
markers	I:C0005516
worsened	O
over	O
the	O
first	O
5	O
weeks	O
while	O
all	O
patient	B:C2987124
-	I:C2987124
reported	I:C2987124
outcomes	I:C2987124
improved	O
during	O
this	O
time	O
,	O
regardless	O
of	O
treatment	O
group	O
.	O

Patient	B:C2987124
-	I:C2987124
reported	I:C2987124
outcomes	I:C2987124
did	O
not	O
differ	O
between	O
patients	O
receiving	O
corticosteroid	O
injections	O
and	O
the	O
placebo	O
group	O
.	O

Patient	O
-	I:C2987124
reported	I:C2987124
outcomes	I:C2987124
did	O
not	O
differ	O
between	O
patients	O
receiving	O
corticosteroid	B:C3536709
injections	O
and	O
the	O
placebo	O
group	O
.	O

Patient	O
-	I:C2987124
reported	I:C2987124
outcomes	I:C2987124
did	O
not	O
differ	O
between	O
patients	O
receiving	O
corticosteroid	O
injections	B:C0021485
and	O
the	O
placebo	O
group	O
.	O

Patient	O
-	I:C2987124
reported	I:C2987124
outcomes	I:C2987124
did	O
not	O
differ	O
between	O
patients	O
receiving	O
corticosteroid	O
injections	O
and	O
the	O
placebo	B:C1696465
group	O
.	O

However	O
,	O
increases	O
in	O
C	B:C3849640
-	I:C3849640
telopeptide	I:C3849640
of	I:C3849640
type	I:C3849640
II	I:C3849640
collagen	I:C3849640
(	O
CTX	O
-	I:C3849640
II	I:C3849640
)	O
,	O
associated	O
with	O
collagen	O
type	I:C0009331
II	I:C0009331
breakdown	O
,	O
were	O
significantly	O
greater	O
in	O
the	O
placebo	O
group	O
(	O
1.32	O
±	O
1.10	O
ng	O
/	O
mL	O
)	O
than	O
in	O
either	O
of	O
the	O
groups	O
that	O
received	O
the	O
corticosteroid	O
injection	O
within	O
the	O
first	O
several	O
days	O
after	O
injury	O
(	O
group	O
1	I:C0441861
:	O
0.23	O
±	O
0.27	O
ng/mL	O
[	O
P	O
=	O
.01	O
]	O
;	O
group	O
3	I:C0441869
:	O
0.19	O
±	O
0.34	O
ng/mL	O
[	O
P	O
=	O
.01	O
]	O
)	O
.	O

However	O
,	O
increases	O
in	O
C	O
-	I:C3849640
telopeptide	I:C3849640
of	I:C3849640
type	I:C3849640
II	I:C3849640
collagen	I:C3849640
(	O
CTX	B:C3849640
-	I:C3849640
II	I:C3849640
)	O
,	O
associated	O
with	O
collagen	O
type	I:C0009331
II	I:C0009331
breakdown	O
,	O
were	O
significantly	O
greater	O
in	O
the	O
placebo	O
group	O
(	O
1.32	O
±	O
1.10	O
ng	O
/	O
mL	O
)	O
than	O
in	O
either	O
of	O
the	O
groups	O
that	O
received	O
the	O
corticosteroid	O
injection	O
within	O
the	O
first	O
several	O
days	O
after	O
injury	O
(	O
group	O
1	I:C0441861
:	O
0.23	O
±	O
0.27	O
ng/mL	O
[	O
P	O
=	O
.01	O
]	O
;	O
group	O
3	I:C0441869
:	O
0.19	O
±	O
0.34	O
ng/mL	O
[	O
P	O
=	O
.01	O
]	O
)	O
.	O

However	O
,	O
increases	O
in	O
C	O
-	I:C3849640
telopeptide	I:C3849640
of	I:C3849640
type	I:C3849640
II	I:C3849640
collagen	I:C3849640
(	O
CTX	O
-	I:C3849640
II	I:C3849640
)	O
,	O
associated	O
with	O
collagen	B:C0009331
type	I:C0009331
II	I:C0009331
breakdown	O
,	O
were	O
significantly	O
greater	O
in	O
the	O
placebo	O
group	O
(	O
1.32	O
±	O
1.10	O
ng	O
/	O
mL	O
)	O
than	O
in	O
either	O
of	O
the	O
groups	O
that	O
received	O
the	O
corticosteroid	O
injection	O
within	O
the	O
first	O
several	O
days	O
after	O
injury	O
(	O
group	O
1	I:C0441861
:	O
0.23	O
±	O
0.27	O
ng/mL	O
[	O
P	O
=	O
.01	O
]	O
;	O
group	O
3	I:C0441869
:	O
0.19	O
±	O
0.34	O
ng/mL	O
[	O
P	O
=	O
.01	O
]	O
)	O
.	O

However	O
,	O
increases	O
in	O
C	O
-	I:C3849640
telopeptide	I:C3849640
of	I:C3849640
type	I:C3849640
II	I:C3849640
collagen	I:C3849640
(	O
CTX	O
-	I:C3849640
II	I:C3849640
)	O
,	O
associated	O
with	O
collagen	O
type	I:C0009331
II	I:C0009331
breakdown	B:C1157968
,	O
were	O
significantly	O
greater	O
in	O
the	O
placebo	O
group	O
(	O
1.32	O
±	O
1.10	O
ng	O
/	O
mL	O
)	O
than	O
in	O
either	O
of	O
the	O
groups	O
that	O
received	O
the	O
corticosteroid	O
injection	O
within	O
the	O
first	O
several	O
days	O
after	O
injury	O
(	O
group	O
1	I:C0441861
:	O
0.23	O
±	O
0.27	O
ng/mL	O
[	O
P	O
=	O
.01	O
]	O
;	O
group	O
3	I:C0441869
:	O
0.19	O
±	O
0.34	O
ng/mL	O
[	O
P	O
=	O
.01	O
]	O
)	O
.	O

However	O
,	O
increases	O
in	O
C	O
-	I:C3849640
telopeptide	I:C3849640
of	I:C3849640
type	I:C3849640
II	I:C3849640
collagen	I:C3849640
(	O
CTX	O
-	I:C3849640
II	I:C3849640
)	O
,	O
associated	O
with	O
collagen	O
type	I:C0009331
II	I:C0009331
breakdown	O
,	O
were	O
significantly	O
greater	O
in	O
the	O
placebo	B:C1696465
group	O
(	O
1.32	O
±	O
1.10	O
ng	O
/	O
mL	O
)	O
than	O
in	O
either	O
of	O
the	O
groups	O
that	O
received	O
the	O
corticosteroid	O
injection	O
within	O
the	O
first	O
several	O
days	O
after	O
injury	O
(	O
group	O
1	I:C0441861
:	O
0.23	O
±	O
0.27	O
ng/mL	O
[	O
P	O
=	O
.01	O
]	O
;	O
group	O
3	I:C0441869
:	O
0.19	O
±	O
0.34	O
ng/mL	O
[	O
P	O
=	O
.01	O
]	O
)	O
.	O

However	O
,	O
increases	O
in	O
C	O
-	I:C3849640
telopeptide	I:C3849640
of	I:C3849640
type	I:C3849640
II	I:C3849640
collagen	I:C3849640
(	O
CTX	O
-	I:C3849640
II	I:C3849640
)	O
,	O
associated	O
with	O
collagen	O
type	I:C0009331
II	I:C0009331
breakdown	O
,	O
were	O
significantly	O
greater	O
in	O
the	O
placebo	O
group	O
(	O
1.32	O
±	O
1.10	O
ng	O
/	O
mL	O
)	O
than	O
in	O
either	O
of	O
the	O
groups	O
that	O
received	O
the	O
corticosteroid	B:C3536709
injection	O
within	O
the	O
first	O
several	O
days	O
after	O
injury	O
(	O
group	O
1	I:C0441861
:	O
0.23	O
±	O
0.27	O
ng/mL	O
[	O
P	O
=	O
.01	O
]	O
;	O
group	O
3	I:C0441869
:	O
0.19	O
±	O
0.34	O
ng/mL	O
[	O
P	O
=	O
.01	O
]	O
)	O
.	O

However	O
,	O
increases	O
in	O
C	O
-	I:C3849640
telopeptide	I:C3849640
of	I:C3849640
type	I:C3849640
II	I:C3849640
collagen	I:C3849640
(	O
CTX	O
-	I:C3849640
II	I:C3849640
)	O
,	O
associated	O
with	O
collagen	O
type	I:C0009331
II	I:C0009331
breakdown	O
,	O
were	O
significantly	O
greater	O
in	O
the	O
placebo	O
group	O
(	O
1.32	O
±	O
1.10	O
ng	O
/	O
mL	O
)	O
than	O
in	O
either	O
of	O
the	O
groups	O
that	O
received	O
the	O
corticosteroid	O
injection	B:C0021485
within	O
the	O
first	O
several	O
days	O
after	O
injury	O
(	O
group	O
1	I:C0441861
:	O
0.23	O
±	O
0.27	O
ng/mL	O
[	O
P	O
=	O
.01	O
]	O
;	O
group	O
3	I:C0441869
:	O
0.19	O
±	O
0.34	O
ng/mL	O
[	O
P	O
=	O
.01	O
]	O
)	O
.	O

However	O
,	O
increases	O
in	O
C	O
-	I:C3849640
telopeptide	I:C3849640
of	I:C3849640
type	I:C3849640
II	I:C3849640
collagen	I:C3849640
(	O
CTX	O
-	I:C3849640
II	I:C3849640
)	O
,	O
associated	O
with	O
collagen	O
type	I:C0009331
II	I:C0009331
breakdown	O
,	O
were	O
significantly	O
greater	O
in	O
the	O
placebo	O
group	O
(	O
1.32	O
±	O
1.10	O
ng	O
/	O
mL	O
)	O
than	O
in	O
either	O
of	O
the	O
groups	O
that	O
received	O
the	O
corticosteroid	O
injection	O
within	O
the	O
first	O
several	O
days	O
after	O
injury	B:C3263723
(	O
group	O
1	I:C0441861
:	O
0.23	O
±	O
0.27	O
ng/mL	O
[	O
P	O
=	O
.01	O
]	O
;	O
group	O
3	I:C0441869
:	O
0.19	O
±	O
0.34	O
ng/mL	O
[	O
P	O
=	O
.01	O
]	O
)	O
.	O

However	O
,	O
increases	O
in	O
C	O
-	I:C3849640
telopeptide	I:C3849640
of	I:C3849640
type	I:C3849640
II	I:C3849640
collagen	I:C3849640
(	O
CTX	O
-	I:C3849640
II	I:C3849640
)	O
,	O
associated	O
with	O
collagen	O
type	I:C0009331
II	I:C0009331
breakdown	O
,	O
were	O
significantly	O
greater	O
in	O
the	O
placebo	O
group	O
(	O
1.32	O
±	O
1.10	O
ng	O
/	O
mL	O
)	O
than	O
in	O
either	O
of	O
the	O
groups	O
that	O
received	O
the	O
corticosteroid	O
injection	O
within	O
the	O
first	O
several	O
days	O
after	O
injury	O
(	O
group	B:C0441861
1	I:C0441861
:	O
0.23	O
±	O
0.27	O
ng/mL	O
[	O
P	O
=	O
.01	O
]	O
;	O
group	O
3	I:C0441869
:	O
0.19	O
±	O
0.34	O
ng/mL	O
[	O
P	O
=	O
.01	O
]	O
)	O
.	O

However	O
,	O
increases	O
in	O
C	O
-	I:C3849640
telopeptide	I:C3849640
of	I:C3849640
type	I:C3849640
II	I:C3849640
collagen	I:C3849640
(	O
CTX	O
-	I:C3849640
II	I:C3849640
)	O
,	O
associated	O
with	O
collagen	O
type	I:C0009331
II	I:C0009331
breakdown	O
,	O
were	O
significantly	O
greater	O
in	O
the	O
placebo	O
group	O
(	O
1.32	O
±	O
1.10	O
ng	O
/	O
mL	O
)	O
than	O
in	O
either	O
of	O
the	O
groups	O
that	O
received	O
the	O
corticosteroid	O
injection	O
within	O
the	O
first	O
several	O
days	O
after	O
injury	O
(	O
group	O
1	I:C0441861
:	O
0.23	O
±	O
0.27	O
ng/mL	O
[	O
P	O
=	O
.01	O
]	O
;	O
group	B:C0441869
3	I:C0441869
:	O
0.19	O
±	O
0.34	O
ng/mL	O
[	O
P	O
=	O
.01	O
]	O
)	O
.	O

posttraumatic	B:C2894027
osteoarthritis	I:C2894027
begins	O
at	O
the	O
time	O
of	O
injury	O
and	O
results	O
early	O
on	O
in	O
dramatic	O
matrix	O
changes	O
in	O
the	O
knee	O
.	O

posttraumatic	O
osteoarthritis	I:C2894027
begins	O
at	O
the	O
time	O
of	O
injury	B:C3263723
and	O
results	O
early	O
on	O
in	O
dramatic	O
matrix	O
changes	O
in	O
the	O
knee	O
.	O

posttraumatic	O
osteoarthritis	I:C2894027
begins	O
at	O
the	O
time	O
of	O
injury	O
and	O
results	O
early	O
on	O
in	O
dramatic	O
matrix	B:C0005962
changes	O
in	O
the	O
knee	O
.	O

posttraumatic	O
osteoarthritis	I:C2894027
begins	O
at	O
the	O
time	O
of	O
injury	O
and	O
results	O
early	O
on	O
in	O
dramatic	O
matrix	O
changes	O
in	O
the	O
knee	B:C0022742
.	O

However	O
,	O
it	O
is	O
encouraging	O
that	O
early	O
intervention	B:C0184661
with	O
an	O
anti-inflammatory	O
agent	I:C0003209
was	O
able	O
to	O
affect	O
biomarkers	O
of	O
chondral	O
degeneration	O
.	O

However	O
,	O
it	O
is	O
encouraging	O
that	O
early	O
intervention	O
with	O
an	O
anti-inflammatory	B:C0003209
agent	I:C0003209
was	O
able	O
to	O
affect	O
biomarkers	O
of	O
chondral	O
degeneration	O
.	O

However	O
,	O
it	O
is	O
encouraging	O
that	O
early	O
intervention	O
with	O
an	O
anti-inflammatory	O
agent	I:C0003209
was	O
able	O
to	O
affect	O
biomarkers	B:C0005516
of	O
chondral	O
degeneration	O
.	O

Should	O
early	O
intervention	B:C0184661
lead	O
to	O
meaningful	O
changes	O
in	O
either	O
the	O
onset	O
or	O
severity	O
of	O
symptomatic	O
posttraumatic	O
osteoarthritis	I:C2894027
,	O
the	O
current	O
treatment	O
paradigm	O
for	O
patients	O
with	O
ACL	O
injury	I:C2584975
may	O
have	O
to	O
be	O
restructured	O
to	O
include	O
early	O
aspiration	O
and	O
intra-articular	O
intervention	O
.	O

Should	O
early	O
intervention	O
lead	O
to	O
meaningful	O
changes	O
in	O
either	O
the	O
onset	O
or	O
severity	O
of	O
symptomatic	O
posttraumatic	B:C2894027
osteoarthritis	I:C2894027
,	O
the	O
current	O
treatment	O
paradigm	O
for	O
patients	O
with	O
ACL	O
injury	I:C2584975
may	O
have	O
to	O
be	O
restructured	O
to	O
include	O
early	O
aspiration	O
and	O
intra-articular	O
intervention	O
.	O

Should	O
early	O
intervention	O
lead	O
to	O
meaningful	O
changes	O
in	O
either	O
the	O
onset	O
or	O
severity	O
of	O
symptomatic	O
posttraumatic	O
osteoarthritis	I:C2894027
,	O
the	O
current	O
treatment	O
paradigm	O
for	O
patients	O
with	O
ACL	B:C2584975
injury	I:C2584975
may	O
have	O
to	O
be	O
restructured	O
to	O
include	O
early	O
aspiration	O
and	O
intra-articular	O
intervention	O
.	O

Should	O
early	O
intervention	O
lead	O
to	O
meaningful	O
changes	O
in	O
either	O
the	O
onset	O
or	O
severity	O
of	O
symptomatic	O
posttraumatic	O
osteoarthritis	I:C2894027
,	O
the	O
current	O
treatment	O
paradigm	O
for	O
patients	O
with	O
ACL	O
injury	I:C2584975
may	O
have	O
to	O
be	O
restructured	O
to	O
include	O
early	O
aspiration	B:C0349707
and	O
intra-articular	O
intervention	O
.	O

Should	O
early	O
intervention	O
lead	O
to	O
meaningful	O
changes	O
in	O
either	O
the	O
onset	O
or	O
severity	O
of	O
symptomatic	O
posttraumatic	O
osteoarthritis	I:C2894027
,	O
the	O
current	O
treatment	O
paradigm	O
for	O
patients	O
with	O
ACL	O
injury	I:C2584975
may	O
have	O
to	O
be	O
restructured	O
to	O
include	O
early	O
aspiration	O
and	O
intra-articular	O
intervention	B:C0184661
.	O

